Intersubtype Differences in the effect of a rare p24 Gag mutation on HIV-1 replicative fitness

Journal of Virology

Volumn 86, Issue 24, 2012, Pages 13423-13433

  Chopera, Denis R ^a,b,c   Cotton, Laura A ^b   Zawaira, Alexander ^d   Mann, Jaclyn K ^e   Ngandu, Nobubelo K ^a   Ntale, Roman ^a   Carlson, Jonathan M ^f   Mlisana, Koleka ^g   Woodman, Zenda ^h   Rosa, Debra de Assis ⁱ   Martin, Eric ^b   Miura, Toshiyuki ^j   Pereyra, Florencia ^k   Walker, Bruce D ^k   Gray, Clive M ^h   Martin, Darren P ^a   Ndung'u, Thumbi ^e   Brockman, Mark A ^b,c   Karim, Salim Abdool ^g   Brumme, Zabrina L ^b,c   Williamson, Carolyn ^a   more..

^a NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^b SIMON FRASER UNIVERSITY   (Canada)

^c BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^d DSI CSIR Nanotechnology Innovation Centre   (South Africa)

^e UNIVERSITY OF KWAZULU NATAL   (South Africa)

^f MICROSOFT RESEARCH   (United States)

^g UNIVERSITY OF KWAZULU NATAL   (South Africa)

^h UNIVERSITY OF CAPE TOWN   (South Africa)

ⁱ NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^j UNIVERSITY OF TOKYO   (Japan)

^k MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALLELE; ARTICLE; CODON; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC DIFFERENCE; HLA TYPING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; MAJOR CLINICAL STUDY; NONHUMAN; P24 GAG GENE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SITE DIRECTED MUTAGENESIS; VIRUS GENE; VIRUS LOAD; VIRUS MUTANT; VIRUS REPLICATION;

AMINO ACID SEQUENCE; COHORT STUDIES; GENES, GAG; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY, AMINO ACID; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84870679723     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02171-12     Document Type: Article

References (53)

1. Abraha A, et al. 2009. CCR5-and CXCR4-tropic subtype C human immunodeficiency virus type 1 isolates have a lower level of pathogenic fitness than other dominant group M subtypes: implications for the epidemic. J. Virol. 83:5592-5605.
2. Allen TM, Altfeld M. 2008. Crippling HIV one mutation at a time. J. Exp. Med. 205:1003-1007.
3. Altfeld M, Allen TM. 2006. Hitting HIV where it hurts: an alternative approach to HIV vaccine design. Trends Immunol. 27:504-510.
4. Avila-Rios S, et al. 2009. Unique features of HLA-mediated HIV evolution in a Mexican cohort: a comparative study. Retrovirology 6:72.
5. Bailey JR, Williams TM, Siliciano RF, Blankson JN. 2006. Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J. Exp. Med. 203:1357-1369.
6. Boutwell CL, Rowley CF, Essex M. 2009. Reduced viral replication capacity of human immunodeficiency virus type 1 subtype C caused by cytotoxic-T-lymphocyte escape mutations in HLA-B57 epitopes of capsid protein. J. Virol. 83:2460-2468.
7. Brockman MA, et al. 2010. Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection. J. Virol. 84:11937-11949.
8. Brockman MA, et al. 2007. Escape and compensation from early HLAB57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. J.Virol. 81:12608-12618.
9. Brockman MA, Tanzi GO, Walker BD, Allen TM. 2006. Use of a novel GFP reporter cell line to examine replication capacity of CXCR4-and CCR5-tropic HIV-1 by flow cytometry. J. Virol. Methods 131:134-142.
10. Brumme ZL, et al. 2009. HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol, and Nef proteins. PLoS One 4:e6687. doi: 10.1371/journal.pone.0006687.
11. Brumme ZL, et al. 2011. Reduced replication capacity of NL4-3 recombinant viruses encoding reverse transcriptase-integrase sequences from HIV-1 elite controllers. J. Acquir. Immune Defic. Syndr. 56:100-108.
12. Brumme ZL, Walker BD. 2009. Tracking the culprit: HIV-1 evolution and immune selection revealed by single-genome amplification. J. Exp. Med. 206:1215-1218.
13. Buonaguro L, Tornesello ML, Buonaguro FM. 2007. Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. J. Virol. 81:10209-10219.
14. Carlson JM, et al. 2008. Phylogenetic dependency networks: inferring patterns of CTL escape and codon covariation in HIV-1 Gag. PLoS Comput. Biol. 4:e1000225. doi:10.1371/journal.pcbi.1000225.
15. Carlson JM, et al. 2012. Widespread impact of HLA restriction on immune control and escape pathways of HIV-1. J. Virol. 86:5230-5243.
16. Chopera DR, et al. 2011. Virological and immunological factors associated with HIV-1 differential disease progression in HLA-B 58:01-positive individuals. J. Virol. 85:7070-7080.
17. Chopera DR, et al. 2008. Transmission of HIV-1 CTL escape variants provides HLA-mismatched recipients with a survival advantage. PLoS Pathog. 4:e1000033. doi:10.1371/journal.ppat.1000033.
18. Chopera DR, Wright JK, Brockman MA, Brumme ZL. 2011. Immunemediated attenuation of HIV-1. Future Virol. 6:917-928.
19. Cotton LA, et al. 2012. HLA class I sequence-based typing using DNA recovered from frozen plasma. J. Immunol. Methods 382:40-47.
20. Coutsinos D, et al. 2009. Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1. J. Virol. 83:2029-2033.
21. Crawford H, et al. 2009. Evolution of HLA-B*5703 HIV-1 escape mutations in HLA-B*5703-positive individuals and their transmission recipients. J. Exp. Med. 206:909-921.
22. Crawford H, et al. 2007. Compensatory mutation partially restores fitness and delays reversion of escape mutation within the immunodominant HLA-B*5703-restricted Gag epitope in chronic human immunodeficiency virus type 1 infection. J. Virol. 81:8346-8351.
23. Gamble TR, et al. 1996. Crystal structure of human cyclophilin A bound o the amino-terminal domain of HIV-1 capsid. Cell 87:1285-1294.
24. Gatanaga H, et al. 2006. Altered HIV-1 Gag protein interactions with cyclophilin A (CypA) on the acquisition of H219Q and H219P substitutions in the CypA binding loop. J. Biol. Chem. 281:1241-1250.
25. John M, et al. 2010. Adaptive interactions between HLA and HIV-1: highly divergent selection imposed by HLA class I molecules with common supertype motifs. J. Immunol. 184:4368-4377.
26. Kiepiela P, et al. 2004. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 432:769-775.
27. Listgarten J, et al. 2008. Statistical resolution of ambiguous HLA typing data. PLoS Comput. Biol. 4:e1000016. doi:10.1371/journal.pcbi.1000016.
28. Martinez-Picado J, et al. 2006. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J. Virol. 80:3617-3623.
29. Maupetit J, Derreumaux P, Tuffery P. 2009. PEP-FOLD: an online resource for de novo peptide structure prediction. Nucleic Acids Res. 37: W498-W503.
30. McGuffin LJ, Bryson K, Jones DT. 2000. The PSIPRED protein structure prediction server. Bioinformatics 16:404-405.
31. Miura T, et al. 2008. Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes. J. Virol. 82:8422-8430.
32. Miura T, et al. 2009. HLA-associated alterations in replication capacity of chimeric NL4-3 viruses carrying gag-protease from elite controllers of human immunodeficiency virus type 1. J. Virol. 83:140-149.
33. Miura T, et al. 2009. HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte recognition. J. Virol. 83:2743-2755.
34. Pereyra F, et al. 2008. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J. Infect. Dis. 197:563-571.
35. Rodrigo AG, et al. 1997. Quantitation of target molecules from polymerase chain reaction-based limiting dilution assays. AIDS Res. Hum. Retroviruses 13:737-742.
36. Rolland M, et al. 2010. Amino-acid co-variation in HIV-1 Gag subtype C: HLA-mediated selection pressure and compensatory dynamics. PLoS One 5:e12463. doi:10.1371/journal.pone.0012463.
37. Rousseau CM, et al. 2008. HLA class-I driven evolution of human immunodeficiency virus type 1 subtype C proteome: immune escape and viral load. J. Virol. 82:6434-6446.
38. Schaller T, et al. 2011. HIV-1 capsid-cyclophilin interactions determine nuclear import pathway, integration targeting and replication efficiency. PLoS Pathog. 7:e1002439. doi:10.1371/journal.ppat.1002439.
39. Schneidewind A, et al. 2008. Structural and functional constraints limit options for cytotoxic T-lymphocyte escape in the immunodominant HLA-B27-restricted epitope in human immunodeficiency virus type 1 capsid. J. Virol. 82:5594-5605.
40. Schneidewind A, et al. 2007. Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J. Virol. 81:12382-12393.
41. Soares EA, et al. 2009. Mutation T74S in HIV-1 subtype B and C proteases resensitizes them to ritonavir and indinavir and confers fitness advantage. J. Antimicrob. Chemother. 64:938-944.
42. Sokolskaja E, Sayah DM, Luban J. 2004. Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity. J. Virol. 78: 12800-12808.
43. Storey JD, Tibshirani R. 2003. Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. U. S. A. 100:9440-9445.
44. Tang C, Ndassa Y, Summers MF. 2002. Structure of the N-terminal 283-residue fragment of the immature HIV-1 Gag polyprotein. Nat. Struct. Biol. 9:537-543.
45. Taylor BS, Hammer SM. 2008. The challenge of HIV-1 subtype diversity. N. Engl. J. Med. 359:1965-1966.
46. Thevenet P, et al. 2012. PEP-FOLD: an updated de novo structure prediction server for both linear and disulfide bonded cyclic peptides. Nucleic Acids Res. 40:W288-W293.
47. Thompson JD, Higgins DG, Gibson TJ. 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22:4673-4680.
48. van Loggerenberg F, et al. 2008. Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. PLoS One 3:e1954. doi:10.1371/journal. pone.0001954.
49. Wright J, et al. 2010. Gag-protease-mediated replication capacity in HIV-1 subtype C chronic infection: associations with HLA type and clinical parameters. J. Virol. 84:10820-10831.
50. Wright JK, et al. 2012. Impact of HLA-B*81-associated mutations in HIV-1 Gag on viral replication capacity. J. Virol. 86:3193-3199.
51. Wright JK, et al. 2011. Influence of gag-protease-mediated replication capacity on disease progression in individuals recently, infected with HIV-1 subtype C. J. Virol. 85:3996-4006.
52. Xu HT, et al. 2009. Effects of the K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance. Retrovirology 6:14.
53. Yusim K, et al. 2009. HIV molecular immunology. Publication LA-UR 09-05941. Los Alamos National Laboratory, Theoretical Biology and Biophysics, Los Alamos, NM.